Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (27)
Ben Xu, Chang-wei Yuan & Jia-en Zhang. (2022) Curcumin Inhibits Proliferation of Renal Cell Carcinoma in vitro and in vivo by Regulating miR-148/ADAMTS18 through Suppressing Autophagy. Chinese Journal of Integrative Medicine.
Crossref
Crossref
Muhammad Ashar Ali, Syed S. Shah, Nayha Tahir, Sana Rehman, Memoona Saeed, Shammas Farooq Bajwa, Rimsha Ali, Wajeeha Aiman & Muhammad Yasir Anwar. (2022) Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta‐analysis. Journal of Neuroendocrinology 34:7.
Crossref
Crossref
Yien Xiang, Ge Zheng, Jianfeng Zhong, Jiyao Sheng & Hanjiao Qin. (2022) Advances in Renal Cell Carcinoma Drug Resistance Models. Frontiers in Oncology 12.
Crossref
Crossref
María Virumbrales-Muñoz, Jose M. Ayuso, Jack R. Loken, Kathryn M. Denecke, Shujah Rehman, Melissa C. Skala, E. Jason Abel & David J. Beebe. (2022) Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy. Biomaterials 283, pages 121454.
Crossref
Crossref
Zihao Wang, Mengqi Chang, Yanruo Zhang, Gang Zhou, Penghao Liu, Jizhong Lou, Yuekun Wang, Yuan Zhang, Xiaopeng Guo, Yaning Wang, Xinjie Bao, Wei Lian, Yu Wang, Renzhi Wang, Wenbin Ma, Bing Xing & Jun Gao. (2022) Multi-Omics Investigations Revealed Underlying Molecular Mechanisms Associated With Tumor Stiffness and Identified Sunitinib as a Potential Therapy for Reducing Stiffness in Pituitary Adenomas. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Jing Liang, Shouqi Wang, Guowei Zhang, Baoyu He, Qingli Bie & Bin Zhang. (2021) A New Antitumor Direction: Tumor-Specific Endothelial Cells. Frontiers in Oncology 11.
Crossref
Crossref
Revati Sharma, Elif Kadife, Mark Myers, George Kannourakis, Prashanth Prithviraj & Nuzhat Ahmed. (2021) Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Osama M. Soltan, Mai E. Shoman, Salah A. Abdel-Aziz, Atsushi Narumi, Hiroyuki Konno & Mohamed Abdel-Aziz. (2021) Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. European Journal of Medicinal Chemistry 225, pages 113768.
Crossref
Crossref
Matthew C. Hernandez, Jennifer L. Leiting, Vidhu B. Joshi, Lin Yang, Hon Leong, Ryan M. Thomas, Jason Fleming & Mark J. Truty. (2020) Patient-derived xenografts in surgical oncology: A short research review. Surgery 168:6, pages 1021-1025.
Crossref
Crossref
Jianming Xu, Lin Shen, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, Tianshu Liu, Yuxian Bai, Ying Yuan, Xingya Li, Xiuwen Wang, Jia Chen, Jieer Ying, Xianjun Yu, Shukui Qin, Xianglin Yuan, Tao Zhang, Yanhong Deng, Dianrong Xiu, Ying Cheng, Min Tao, Ru Jia, Wei Wang, Jing Li, Songhua Fan, Mengye Peng & Weiguo Su. (2020) Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology 21:11, pages 1500-1512.
Crossref
Crossref
Ke Li, Sheng Ma, Liyan Miao, Songhua Fan, Bin Pan, Weihan Zhang, Weiguo Su, Yating Xiong, Zheming Gu, Lian Guo & Yang Sai. (2020) Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans. Current Drug Metabolism 21:5, pages 357-367.
Crossref
Crossref
Alessia Cimadamore, Gaetano Aurilio, Franco Nolé, Francesco Massari, Marina Scarpelli, Matteo Santoni, Antonio Lopez-Beltran, Liang Cheng & Rodolfo Montironi. (2020) Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells 9:6, pages 1495.
Crossref
Crossref
Silvia Ghione, Nesrine Mabrouk, Catherine Paul, Ali Bettaieb & Stéphanie Plenchette. (2020) Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. Biochemical Pharmacology 176, pages 113855.
Crossref
Crossref
Yash Dara, Nicholas Salgia & Sumanta K. Pal. 2020. Oncology in the Precision Medicine Era. Oncology in the Precision Medicine Era
123
133
.
Wei Jiang & Meiju Ji. (2019) Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Seminars in Cancer Biology 59, pages 3-22.
Crossref
Crossref
Anna Brodziak, Paweł Sobczuk, Ewa Bartnik, Michał Fiedorowicz, Camillo Porta, Cezary Szczylik & Anna M. Czarnecka. (2019) Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. Nature Reviews Urology 16:11, pages 655-673.
Crossref
Crossref
Francesco Massari, Vincenzo Di Nunno, Matteo Santoni, Lidia Gatto, Claudia Caserta, Franco Morelli, Elena Zafarana, Francesco Carrozza, Alessandra Mosca, Veronica Mollica, Roberto Iacovelli, Roberto Sabbatini, Camillo Porta & Sergio Bracarda. (2019) Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology 142, pages 141-152.
Crossref
Crossref
Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao, Wei Wang, Ke Cheng, Chunxia Su, Ye Hua, Chuan Qi, Jing Li, Wei Wang, Ke Li, Qiaoling Sun, Yongxin Ren & Weiguo Su. (2019) Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. Clinical Cancer Research 25:12, pages 3486-3494.
Crossref
Crossref
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi & Francesco Massari. (2019) Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers 11:6, pages 830.
Crossref
Crossref
Cinta Hierro & Josep Tabernero. 2019. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy
101
121
.
Chris P. Miller, Connor Tsuchida, Ying Zheng, Jonathan Himmelfarb & Shreeram Akilesh. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:6, pages 610-620.
Crossref
Crossref
Rajesh N. Gacche & Yehuda G. Assaraf. (2018) Redundant angiogenic signaling and tumor drug resistance. Drug Resistance Updates 36, pages 47-76.
Crossref
Crossref
Yi-Feng Gu, Shannon Cohn, Alana Christie, Tiffani McKenzie, Nicholas Wolff, Quyen N. Do, Ananth J. Madhuranthakam, Ivan Pedrosa, Tao Wang, Anwesha Dey, Meinrad Busslinger, Xian-Jin Xie, Robert E. Hammer, Renée M. McKay, Payal Kapur & James Brugarolas. (2017)
Modeling Renal Cell Carcinoma in Mice:
Bap1
and
Pbrm1
Inactivation Drive Tumor Grade
. Cancer Discovery 7:8, pages 900-917.
Crossref
Crossref
Mario A. Cepeda, Jacob JH. Pelling, Caitlin L. Evered, Hon S. Leong & Sashko Damjanovski. (2017) The cytoplasmic domain of MT1-MMP is dispensable for migration augmentation but necessary to mediate viability of MCF-7 breast cancer cells. Experimental Cell Research 350:1, pages 169-183.
Crossref
Crossref
Barbara J. Bałan, Andrzej K. Siwicki, Krzysztof Pastewka, Urszula Demkow, Piotr Skopiński, Ewa Skopińska-Różewska, Sławomir Lewicki & Robert Zdanowski. 2017. Clinical Research and Practice. Clinical Research and Practice
91
104
.
Mario A. Cepeda, Jacob J. H. Pelling, Caitlin L. Evered, Karla C. Williams, Zoey Freedman, Ioana Stan, Jessica A. Willson, Hon S. Leong & Sashko Damjanovski. (2016) Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells. Molecular Cancer 15:1.
Crossref
Crossref
Qian Jing, Yuanyuan Wang, Hao Liu, Xiaowei Deng, Lin Jiang, Rui Liu, Haixing Song & Jingyi Li. (2016) FGFs: crucial factors that regulate tumour initiation and progression. Cell Proliferation 49:4, pages 438-447.
Crossref
Crossref